{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T01:22:17Z","timestamp":1771636937187,"version":"3.50.1"},"reference-count":61,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1136\/ard.2007.083022","type":"journal-article","created":{"date-parts":[[2008,4,4]],"date-time":"2008-04-04T00:54:19Z","timestamp":1207270459000},"page":"470-476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["EULAR points to consider for conducting clinical trials in systemic lupus erythematosus"],"prefix":"10.1016","volume":"68","author":[{"given":"C","family":"Gordon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Bertsias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J P A","family":"Ioannidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Boletis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Bombardieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Cervera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Dost\u00e1l","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Font","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I-M","family":"Gilboe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Houssiau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T W J","family":"Huizinga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Isenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C G M","family":"Kallenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M A","family":"Khamashta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J-C","family":"Piette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J S","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Sturfelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Tincani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Van Vollenhoven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D T","family":"Boumpas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2007.083022_bib1","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1681\/ASN.2006090992","article-title":"Severe lupus nephritis: racial differences in presentation and outcome.","volume":"18","author":"Korbet","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1136\/ard.2007.083022_bib2","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/art.21955","article-title":"Mortality in systemic lupus erythematosus.","volume":"54","author":"Bernatsky","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.083022_bib3","doi-asserted-by":"crossref","first-page":"549","DOI":"10.7326\/0003-4819-125-7-199610010-00003","article-title":"Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial.","volume":"125","author":"Gourley","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2007.083022_bib4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/ncprheum0016","article-title":"Optimum therapeutic approaches for lupus nephritis: what therapy and for whom?","volume":"1","author":"Boumpas","year":"2005","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1136\/ard.2007.083022_bib5","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/art.10763","article-title":"LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study.","volume":"48","author":"Alarcon-Segovia","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.083022_bib6","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.berh.2005.05.006","article-title":"New treatments for SLE: cell-depleting and anti-cytokine therapies.","volume":"19","author":"Anolik","year":"2005","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1136\/ard.2007.083022_bib7","first-page":"979","article-title":"Design, quality, and bias in randomized controlled trials of systemic lupus erythematosus.","volume":"30","author":"Karassa","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.083022_bib8","first-page":"1953","article-title":"Systemic Lupus International Collaborating Clinics conference on assessment of lupus flare and quality of life measures in SLE. Systemic Lupus International Collaborating Clinics Group.","volume":"23","author":"Gladman","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.083022_bib9","first-page":"504","article-title":"Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains.","volume":"26","author":"Smolen","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.083022_bib10","first-page":"490","article-title":"Outcome measures to be used in clinical trials in systemic lupus erythematosus.","volume":"26","author":"Strand","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.083022_bib11","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1191\/096120300678828424","article-title":"Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology.","volume":"9","author":"Strand","year":"2000","journal-title":"Lupus"},{"key":"10.1136\/ard.2007.083022_bib12","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.berh.2005.03.010","article-title":"Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices.","volume":"19","author":"Griffiths","year":"2005","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1136\/ard.2007.083022_bib13","doi-asserted-by":"crossref","unstructured":"The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials,. Arthritis Rheum 2006;54:421\u201332.","DOI":"10.1002\/art.21625"},{"key":"10.1136\/ard.2007.083022_bib14","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1136\/ard.2004.023697","article-title":"EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees.","volume":"63","author":"Dougados","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.083022_bib15","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1136\/ard.2007.083030","article-title":"EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints.","volume":"68","author":"Bertsias","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.083022_bib16","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/ard.2006.065854","article-title":"Why we need guidelines for clinical trials in vasculitis and systemic lupus erythematosus.","volume":"66","author":"Mukhtyar","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.083022_bib17","doi-asserted-by":"crossref","unstructured":"Bertsias G, Ioannidis JPA, Boletis J, Bombardieri S, Cervera R, Dostal C, et al. Evidence for selection of end-points for clinical trials in systemic lupus erythematosus (SLE): a systematic literature review. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis Published Online First: 23 April 2008. doi:10.1136\/ard.2007.083030.","DOI":"10.1136\/ard.2007.070367"},{"key":"10.1136\/ard.2007.083022_bib18","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1191\/096120300672904669","article-title":"From BILAG to BLIPS\u2014disease activity assessment in lupus past, present and future.","volume":"9","author":"Isenberg","year":"2000","journal-title":"Lupus"},{"key":"10.1136\/ard.2007.083022_bib19","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/art.1780350606","article-title":"Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.","volume":"35","author":"Bombardier","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.083022_bib20","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000.","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.083022_bib21","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1191\/096120300678828640","article-title":"The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus.","volume":"9","author":"Mosca","year":"2000","journal-title":"Lupus"},{"key":"10.1136\/ard.2007.083022_bib22","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1002\/art.22162","article-title":"Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity.","volume":"54","author":"Yee","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.083022_bib23","doi-asserted-by":"crossref","first-page":"953","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00004","article-title":"The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial.","volume":"142","author":"Buyon","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2007.083022_bib24","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1191\/096120399680411281","article-title":"Classification and definition of major flares in SLE clinical trials.","volume":"8","author":"Petri","year":"1999","journal-title":"Lupus"},{"key":"10.1136\/ard.2007.083022_bib25","first-page":"373","article-title":"The Systemic Lupus International Collaborating Clinics\/American College of Rheumatology (SLICC\/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison.","volume":"27","author":"Gladman","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.083022_bib26","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1017\/S0029665107005514","article-title":"CVD risk in South Asians: the importance of defining adiposity and influence of dietary polyunsaturated fat.","volume":"66","author":"Lovegrove","year":"2007","journal-title":"Proc Nutr Soc"},{"key":"10.1136\/ard.2007.083022_bib27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/heart.83.3.267","article-title":"Racial variation in cardiovascular morbidity and mortality in essential hypertension.","volume":"83","author":"Khattar","year":"2000","journal-title":"Heart"},{"key":"10.1136\/ard.2007.083022_bib28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/sj.jhh.1001371","article-title":"Ethnic differences in blood pressure and the prevalence of hypertension in England.","volume":"16","author":"Lane","year":"2002","journal-title":"J Hum Hypertens"},{"key":"10.1136\/ard.2007.083022_bib29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/qjmed\/92.4.187","article-title":"The management of hypertensive disease in black patients.","volume":"92","author":"Gibbs","year":"1999","journal-title":"QJM"},{"key":"10.1136\/ard.2007.083022_bib30","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/1529-0131(200008)43:8<1801::AID-ANR16>3.0.CO;2-O","article-title":"Damage in systemic lupus erythematosus and its association with corticosteroids.","volume":"43","author":"Zonana-Nacach","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.083022_bib31","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/rheumatology\/35.3.248","article-title":"SLICC\/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus.","volume":"35","author":"Stoll","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.2007.083022_bib32","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1191\/096120301670679959","article-title":"Early damage as measured by the SLICC\/ACR damage index is a predictor of mortality in systemic lupus erythematosus.","volume":"10","author":"Rahman","year":"2001","journal-title":"Lupus"},{"key":"10.1136\/ard.2007.083022_bib33","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1191\/0961203302lu190sa","article-title":"The SLICC damage index: past, present and future.","volume":"11","author":"Dayal","year":"2002","journal-title":"Lupus"},{"key":"10.1136\/ard.2007.083022_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-99-1-1","article-title":"Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up.","volume":"99","author":"Carette","year":"1983","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2007.083022_bib35","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0140-6736(92)92292-N","article-title":"Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis.","volume":"340","author":"Boumpas","year":"1992","journal-title":"Lancet"},{"key":"10.1136\/ard.2007.083022_bib36","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/0003-4819-135-4-200108210-00009","article-title":"Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.","volume":"135","author":"Illei","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2007.083022_bib37","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1191\/096120399680411344","article-title":"Quality of life and economic evaluation in SLE clinical trials.","volume":"8","author":"Gordon","year":"1999","journal-title":"Lupus"},{"key":"10.1136\/ard.2007.083022_bib38","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1191\/0961203303lu440oa","article-title":"Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo.","volume":"12","author":"Strand","year":"2003","journal-title":"Lupus"},{"key":"10.1136\/ard.2007.083022_bib39","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1191\/0961203304lu1083rr","article-title":"Psychosocial research on systemic lupus erythematosus: a literature review.","volume":"13","author":"Seawell","year":"2004","journal-title":"Lupus"},{"key":"10.1136\/ard.2007.083022_bib40","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/rheumatology\/keh605","article-title":"Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL).","volume":"44","author":"Leong","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2007.083022_bib41","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/art.22881","article-title":"Development and validation of a disease-specific health-related quality of life measure, the Lupus QoL, for adults with systemic lupus erythematosus.","volume":"57","author":"McElhone","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.083022_bib42","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/rheumatology\/38.11.1130","article-title":"The association of socio-economic status, race, psychosocial factors and outcome in patients with systemic lupus erythematosus.","volume":"38","author":"Sutcliffe","year":"1999","journal-title":"Rheumatology"},{"key":"10.1136\/ard.2007.083022_bib43","doi-asserted-by":"crossref","first-page":"781","DOI":"10.7326\/0003-4819-141-10-200411160-00009","article-title":"Better reporting of harms in randomized trials: an extension of the CONSORT statement.","volume":"141","author":"Ioannidis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2007.083022_bib44","first-page":"2037","article-title":"Standardized assessment of adverse events in rheumatology clinical trials: summary of the OMERACT 7 drug safety module update.","volume":"32","author":"Lassere","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.083022_bib45","first-page":"2030","article-title":"Challenges and progress in adverse event ascertainment and reporting in clinical trials.","volume":"32","author":"Lassere","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.083022_bib46","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.22470","article-title":"The systemic lupus erythematosus Tri-Nation study: cumulative indirect costs.","volume":"57","author":"Panopalis","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.083022_bib47","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/rheumatology\/keh229","article-title":"The systemic lupus erythematosus Tri-nation Study: absence of a link between health resource use and health outcome.","volume":"43","author":"Clarke","year":"2004","journal-title":"Rheumatology"},{"key":"10.1136\/ard.2007.083022_bib48","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/ard.56.6.382","article-title":"Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease).","volume":"56","author":"Gansauge","year":"1997","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.083022_bib49","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/art.10364","article-title":"Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial.","volume":"46","author":"Petri","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.083022_bib50","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1056\/NEJMoa031855","article-title":"Sequential therapies for proliferative lupus nephritis.","volume":"350","author":"Contreras","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2007.083022_bib51","doi-asserted-by":"crossref","first-page":"657","DOI":"10.7326\/0003-4819-134-8-200104170-00011","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials.","volume":"134","author":"Moher","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2007.083022_bib52","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jama.1996.03540080071033","article-title":"How to report randomized controlled trials. The CONSORT statement.","volume":"276","author":"Rennie","year":"1996","journal-title":"JAMA"},{"key":"10.1136\/ard.2007.083022_bib53","unstructured":"Directive 2001\/20\/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use,. Med Etika Bioet 2002;9:12\u201319."},{"key":"10.1136\/ard.2007.083022_bib54","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/art.20980","article-title":"Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus.","volume":"52","author":"Linnik","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.083022_bib55","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus.","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.083022_bib56","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.083022_bib57","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/01.ASN.0000108969.21691.5D","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited.","volume":"15","author":"Weening","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1136\/ard.2007.083022_bib58","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1523-1755.2004.00443.x","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited.","volume":"65","author":"Weening","year":"2004","journal-title":"Kidney Int"},{"key":"10.1136\/ard.2007.083022_bib59","first-page":"913","article-title":"The rate and pattern of organ damage in late onset systemic lupus erythematosus.","volume":"29","author":"Maddison","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.083022_bib60","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa051135","article-title":"Combined oral contraceptives in women with systemic lupus erythematosus.","volume":"353","author":"Petri","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2007.083022_bib61","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1056\/NEJMoa050817","article-title":"A trial of contraceptive methods in women with systemic lupus erythematosus.","volume":"353","author":"Sanchez-Guerrero","year":"2005","journal-title":"N Engl J Med"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349672442548X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349672442548X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2007.083022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T05:08:29Z","timestamp":1736140109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000349672442548X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S000349672442548X"],"URL":"https:\/\/doi.org\/10.1136\/ard.2007.083022","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EULAR points to consider for conducting clinical trials in systemic lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2007.083022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 2009 Published by Elsevier Inc. Publishing Group and European League Against Rheumatism. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}